These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8603961)

  • 1. Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: results of a phase I/II trial.
    Kovacs JA; Bechtel C; Davey RT; Falloon J; Polis MA; Walker RE; Metcalf JA; Davey V; Piscitelli SC; Baseler M; Dewar R; Salzman NP; Masur H; Lane HC
    J Infect Dis; 1996 Apr; 173(4):840-8. PubMed ID: 8603961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretrovirals plus immunomodulators: didanosine/interferon-alpha combination shows promise.
    Folkers G
    NIAID AIDS Agenda; 1996 Jun; ():8-9. PubMed ID: 11363810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L; Cargnel A; Soranzo ML; Chirianni A; Ferraro T; Di Stefano M; Angarano G
    Antivir Ther; 1999; 4(4):195-202. PubMed ID: 10723498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. Alpha International Coordinating Committee.
    AIDS; 1996 Jul; 10(8):867-80. PubMed ID: 8828744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerance of a triple combination therapy with zidovudine, didanosine and interferon-alpha in seven HIV-infected patients.
    Bissuel F; Trabaud MA; Leriche K; Cotte L; Schlienger I; Rougier P; Trepo C
    AIDS; 1995 Nov; 9(11):1285. PubMed ID: 8561983
    [No Abstract]   [Full Text] [Related]  

  • 7. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.
    Fernández-Cruz E; Lang JM; Frissen J; Furner V; Châteauvert M; Boucher CA; Dowd P; Stevens J
    AIDS; 1995 Sep; 9(9):1025-35. PubMed ID: 8527074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy for infection due to human immunodeficiency virus type 1.
    Caliendo AM; Hirsch MS
    Clin Infect Dis; 1994 Apr; 18(4):516-24. PubMed ID: 7518701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
    Molina JM; Chêne G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM
    J Infect Dis; 1999 Aug; 180(2):351-8. PubMed ID: 10395849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
    Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pancreatic disease in patients with HIV treated with didanosine (DDI)].
    Ortega González E; Martín Herrera A; López de Medrano V; de Lelis FP; Ronda Gasulla FA; Gil Egea M; Ballester Belda E; Herrera Ballester A
    Rev Esp Enferm Dig; 1996 Feb; 88(2):114-7. PubMed ID: 8664067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068.
    Mildvan D; Bassiakos Y; Zucker ML; Hyslop N; Krown SE; Sacks HS; Zachary J; Paredes J; Fessel WJ; Rhame F; Kramer F; Fischl MA; Poiesz B; Wood K; Ruprecht RM; Kim J; Grossberg SE; Kasdan P; Bergé P; Marshak A; Pettinelli C
    Antivir Ther; 1996 Apr; 1(2):77-88. PubMed ID: 11321183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
    Ballesteros AL; Miró O; López S; Fuster D; Videla S; Martínez E; Garrabou G; Salas A; Côté H; Tor J; Rey-Joly C; Planas R; Clotet B; Tural C
    Antivir Ther; 2004 Dec; 9(6):969-77. PubMed ID: 15651755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection.
    Davey RT; Davey VJ; Metcalf JA; Zurlo JJ; Kovacs JA; Falloon J; Polis MA; Zunich KM; Masur H; Lane HC
    J Infect Dis; 1991 Jul; 164(1):43-52. PubMed ID: 1676045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
    Kojima E; Shirasaka T; Anderson BD; Chokekijchai S; Steinberg SM; Broder S; Yarchoan R; Mitsuya H
    J Infect Dis; 1995 May; 171(5):1152-8. PubMed ID: 7751690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs.
    Hayashi K; Fukuda Y; Nakano I; Katano Y; Yokozaki S; Toyoda H; Takamatsu J; Hayakawa T
    Haemophilia; 2000 Nov; 6(6):677-81. PubMed ID: 11122395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
    Skowron G; Kuritzkes DR; Thompson MA; Squires KE; Goodwin SD; Dusak BA; Tolson JM; Stevens M; Yuen GJ; Rooney JF;
    J Infect Dis; 2002 Oct; 186(7):1028-33. PubMed ID: 12232846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.